High-Flying Arrowhead Pharmaceuticals Appoints James Hassard as Chief Commercial Officer

Published : Wednesday, January 8, 2020 | 2:30 AM

Pasadena-based Arrowhead Pharmaceuticals Inc. has announced the appointment of James Hassard to the newly-created position of chief commercial officer.

The company said Hassard will be responsible for driving commercial strategy and building the team and sales and marketing infrastructure necessary to support Arrowhead’s growing pipeline of investigational RNAi therapeutics. He has 25 years of commercial-related experience in the biopharmaceutical industry.

“We are excited to announce the appointment of Jim Hassard as Arrowhead’s chief commercial officer,” Dr. Chris Anzalone, President and CEO of Arrowhead, said. “Jim’s experience and guidance will be critical as we advance our robust pipeline of RNAi therapeutics that target diseases across multiple therapeutic areas.”

As the new chief commercial officer of Arrowhead, Hassard said the company has an enormous opportunity to make a significant difference in patients’ lives with its promising pipeline of RNAi therapeutics.

“The company is at an exciting time in its corporate development, as it intends to have three pivotal studies ongoing this year, and as the commercial strategy and team begin to form,” he said. “I am pleased to lead that strategic process and contribute to the future growth of the company.”

Hassard served as SVP of Marketing and Market Access at Coherus BioSciences since 2016, where he was instrumental in building the commercial organization and commercial capabilities. He co-led the launch of Coherus’ first product, a biosimilar, pegfilgrastim, one of the most successful pharmaceutical launches of 2019.

Prior to his tenure at Coherus, Hassard served as Vice President of Marketing at Medivation, prior to and through its acquisition by Pfizer Pharmaceuticals. From 1999 to 2016, he held multiple increasingly senior commercial roles at Amgen, Inc. across sales and marketing, domestic and international, including an assignment as General Manager of Amgen Portugal. He was responsible for the launch, growth, and subsequent life-cycle management of several oncology and nephrology products, including darbepoetin alfa and cinacalcet.

Before his time at Amgen, Hassard spent several years at Schering Plough Canada, in sales and marketing roles.

He received his Bachelor of Science in pharmacology from the University of Toronto and a master’s in business administration from Nova Southeastern University in Florida.

 

 

 

 

 

blog comments powered by Disqus